Semaglutide Research for Type 2 Diabetes
An evidence-based overview of research examining Semaglutide in the context of type 2 diabetes. This page synthesizes findings from peer-reviewed literature.
Research Summary
Semaglutide was first FDA-approved for type 2 diabetes in 2017 (as Ozempic). In placebo-controlled SUSTAIN 1, HbA1c fell by 1.45 and 1.55 percentage points in the two semaglutide groups at 30 weeks, versus 0.02 points with placebo (PMID:28110911). Those values are trial-specific. The drug improves glycemic control through multiple mechanisms: glucose-dependent insulin secretion, glucagon suppression, and delayed gastric emptying. SUSTAIN-6 showed 26% reduction in major adverse cardiovascular events, establishing cardiovascular benefit. Both injectable (Ozempic, once weekly) and oral (Rybelsus, daily) formulations are available for diabetes. The SOUL trial (2025) confirmed oral semaglutide also reduces cardiovascular events by 14% in high-risk type 2 diabetes patients.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.